TNFRSF9 and neoplasm: For the biologic endpoint of CD8+ CD137+ tumor-infiltrating T cells, multiplex immunohistochemistry (mIHC) was performed on surgical specimens from 8 patients in Arm C. Tumors without an identifiable regions of interest (ROI) that contained epithelial neoplastic cells in the vicinity of TLAs were excluded from the analysis following the same standard established previously9.